Stockreport

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium, Inc.  (EQ) 
Last equillium, inc. earnings: 3/26 04:07 pm Check Earnings Report
PDF Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placeb [Read more]